← Back to Search

Procedure

Customized Scleral Lens for Keratoconus

N/A
Waitlist Available
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights
No Placebo-Only Group

Summary

The goal of the study is to examine the effects of custom front-surface wavefront correction on visual performance, and on neutralization of higher order aberrations, in patients wearing a scleral lens device. The investigators will study patients with keratoconus, the most common type of corneal ectasia, who have already been fitted with the BostonSight BSS (Boston Sight Scleral) for improved visual function.

Eligible Conditions
  • Keratoconus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Normal Vision

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Customized Scleral LensExperimental Treatment1 Intervention
A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Customized Scleral Lens
2018
N/A
~20

Find a Location

Who is running the clinical trial?

Ovitz CorporationUNKNOWN
Boston SightOTHER
5 Previous Clinical Trials
101 Total Patients Enrolled
1 Trials studying Keratoconus
11 Patients Enrolled for Keratoconus
University of RochesterLead Sponsor
870 Previous Clinical Trials
549,775 Total Patients Enrolled
~2 spots leftby Dec 2025